A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04482309

Recruitment Status : Active, not recruiting

First Posted : July 22, 2020

Last Update Posted : February 6, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Daiichi Sankyo Co., Ltd.

Information provided by (Responsible Party):

AstraZeneca

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Actual Primary Completion Date :	June 8, 2023
Estimated Study Completion Date :	July 30, 2027

To Top